Oral treatment of erectile dysfunction: Background, spectrum and limitations;Oral-medikamentöse therapie der erektilen dysfunktion: Grundlagen, spektrum und grenzen

Aktuelle Urologie

Volumn 30, Issue 7, 1999, Pages 449-460

  Altwein, J E ^a   Thon, W F ^b  

^a Urologische Abteilung   (Germany)

^b NONE

Author keywords

Erectile dysfunction; Oral treatment

Indexed keywords

EID: 0033275514     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-8963     Document Type: Article

References (80)

1. Andersson KE, Wagner G. Physiology of Penile Erection. Physiological Review 1995; 75: 191-235
2. De Groat WC, Steers WD. Neuroanatomy and neurophysiology of penile erection. In: Tanagho EA, Lue TF, McClare RD, Hrsg. Contemporary Management of Impotence and Infertility. Baltimore: Williams & Wilkins, 1988. 3-27
3. Feldman HA, Goldstein I et al.. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994; 151: 54-61
4. Braun M, Klotz T, Reifenrath B et al. The "Cologne 8000 men survey" - Prevalence and therapy necessary of men with erectile dysfunction. First International Consultation on Erectile Dysfunction der WHO. Paris, 1-3. Juli 1999.
5. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83-90
6. Montague DK, Barada JH, Belker AM et al. Clinical guidelines on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156: 2007-2011
7. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction.J Urol 1997; 157: 2135-2138
8. Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11: 59-74
9. Rosen RC, Riley A, Wagner G et al. The International Index of Erectile Function: A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830
10. Burnett AL. Nitric oxide in the penis: Physiology and pathology. J Urol 1997; 157: 320-324
11. Wassertheil-Smoller R et al. Effects of antihypertensives on sexual function and quality of life: The TAIM study. Ann lnt Med 1991; 114: 613-620
12. Grimm RH, Grandits GA, Prineas RJ et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8-14
13. Porst H. Therapie der erektilen Dysfunktion. Neuromodulatorische und molekulare Grundlagen. Niere - Blase - Prostata 1998; 23 (1.Suppl.): 13-31
14. Weiske WH. Epidemiologie und Diagnostik der erektilen Dysfunktion. Niere - Blase - Prostata 1998; 23 (1.Suppl.): 5-12
15. Porst H. Editorial Comment. Int J Impot Res 1999; 11: 72-73
16. Akkus E, Alici B, Ökara H et al., Repetition of color doppler ultrasonography: Is it necessary? Int J Impot Res 1998; 10: 51-55
17. Anderson M, Nicholson B, Louie E et al. An analysis of vasculogenic erectile dysfunction as a potential predictor of occult cardiac disease. J Urol 1998; 159: 118A
18. Kaiser FE, Udhoji V et al.. Cardiovascular stress test in patients with vascular impotence. Clin Res 1989; 37: 89A
19. Wessels H, Fuciarelli K, Hansen J et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. J Urol 1998; 160: 389-393
20. Schlatter EKE, Lal S. Treatment of alcoholism using Dent's oral apomorphine method. QJ Stud Alcohol 1972; 33: 430-436
21. Zarrindast MR, Shokravi S, Samini M et al. Opposite influences of dopaminergic receptor subtypes on penile erection. Gen Pharmacol 1992; 23: 671-675
22. Ahlenius S, Larsson K. Apomorphine-and haloperidol-induced effects on male sexual behavior: no evidence for actions due to stimulation of central dopamine autoreceptors. Pharmacol Biochem Behav 1984; 21: 463-466
23. Melis MR, Argiolas A. Nitrit oxide synthase inhibitors prevent apomorphine-and oxytocin-induced penile erection and yawning in male rats. Brain Res Bull 1993; 32: 71-74
24. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992; 46: 755-784
25. Melis MR, Stancampiano R, Gessa GL, Argiolas A. Prevention by morphine of apomorphine-and oxytocin-induced penile erection and yawning. Pharmacol Biochem Behav 1992; 42: 61-66
26. Heaton JPW, Varrin SJ. Effects of castration and exogenous testosterone supplementation in an animal model of penile erection. J Urol 1994; 151: 797-800
27. Andersson KE, Gemalmaz H, Waldeck K et al.. The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat. J Urol 1999; 161: 1707-1712
28. Heaton J. Apomorphine, the central initiator and the matrix of treatment strategies. International Society for Impotence Research; 8. Weltkongreß (24.-28.8. 98 Amsterdam)
29. Padma-Nathan H, Auerbach S, Lewis R et al. Efficacy and safety of apomorphin SL vs. placebo for male erectile dysfunction. J Urol 1999; 161: 214A
30. Lewis R, Agre K, Fromm S et al. Efficacy of apomorphine SL vs. placebo for erectile dysfunction in patients with hypertension. J Urol 1999; 161: 214A
31. Steers WD, De Groat WC. Effects of m-chlorophenylpiperazine on penile and bladder function in rats. Am J Physiol 1989; 257: R1441-R1449
32. 1C/1D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys. EurJ Pharmacol 1993; 243: 227-234
33. Azadzoi KM, Kim N, Wertz JM et al. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992; 147: 220-225
34. Sikora R, Sohn M, Bosshardt R et al. Trazodone in diagnosis and therapy of erectile dysfunction. Int J Impot Res 1992; 4: A100
35. Morales A, Condra M, Owen JA et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987; 137: 1168-1172
36. Riley AJ, Goodman RE, Kellet JM et al.. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. J Sex Martial Ther 1989; 4: 17-25
37. Ellis WJ, Grayhack JT. Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 1963; 89: 895-899
38. Heim N. Sexual behaviour of castrated sex offenders. Arch Sex Behav 1981; 10: 11-19
39. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen therapy. Arch Sex Behav 1983; 12: 59-66
40. Carani C, Scuteri A, Marrama P et al. The effects of testosterone administration and visual erotic stimuli on nocturnal penile tumescence in normal men. Horm Behav 1990; 24: 435-441
41. Reiter WJ, Pycha A, Schatzl G et al.. Dehydroepiandrosterone in the treatment of erectile dysfunction: A prospective, double-blind, randomised, placebo-controlled study. Urology 1999; 53: 590-4; 594-5
42. Becker AJ, Stief CG, Schultheiss D, Truss MC, Jonas U. Pharmakologische Therapie der erektilen Dysfunktion. Urologe A 1998; 37: 503-508
43. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376
44. Burnett AL, Löwenstein CJ, Bredt DS et al. Nitric oxide: A physiological mediator of penile erection. Science 1992; 257: 401-403
45. Zorgniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile function. Int J Impot Res 1994; 6: 33-36
46. Chen J, Wollman Y, Chernichovsky T et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectily dysfunction: Results of a double-blind, randomized, placebo-controlled study. Br J Urol 1999; 83: 269-273
47. Brindley GS. Cavernosal alpha-blockade and human penile erection. J Physiol 1983; 342: 24
48. Stief CG, Bähren W, Gall H, Scherb W, Gallwitz A, Altwein JE. Schwellkörper-Autoinjektionstherapie (SKAT): Erste Erfahrungen bei erektiler Dysfunktion. Urologe A 1986; 25: 63-68
49. Kaplan SA, Reis RB, Kohn IJ et al. Combination therapy using oral alphablockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52: 739-743
50. Goldstein I, Ferguson D. Vasomax Study Group. Efficacy and safety of phentolamine (Vasomax®) for the treatment of erectile dysfunction using a crossover study design. Int J Impot Res 1998; 10: 561
51. Rosen R. α-Blocker therapies for ED, including daxozosine and phentolamine. International Society for Impotence Research; 8. Weltkongreß, Amsterdam 24.-28. 8. 1998
52. Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur Heart J 1993; 14: 141-148
53. Boolell M, Gepi-Attee S, Gingell JC et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261
54. Truss MC, Becker AJ, Ückert S et al. Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future. Br J Urol 1999; 83 (Suppl. 2): 36-41
55. Wallis RM, Corbin JD, Francis SH et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C
56. Morales A, Gingell C, Collins M et al. Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74
57. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 388: 1397-1404
58. Steers WD and the Sildenafil Study Group. Meta-Analysis of the efficacy of sildenafil (Viagra®) in the treatment of severe erectile dysfunction. J Urol 1998; 159: 238A
59. Hartmann U, Meuleman EJH, Cuzin B et al. Sildenafil (Viagra®): Analysis of preferred doses in a European, 6-month, double-blind, placebo-controlled, flexible dose-escalation study in patients with erectile dysfunction. The 8th World Meeting on Impotence Research, 25-28 August 1998, Amsterdam. Int J Impot Res 1998; 10 (Suppl. 3): S 34, Abstract 255
60. Vroege JA. Letter to the Editor. The sexual health inventory for men (IIEF-5). Int J Impot Res 1999; 11: 177
61. Hültling C. Partner's perceptions of efficacy of sildenafil (Viagra®) in the treatment of erectile dysfunction. Int Impot Res 1988; 10 (Suppl. 3): S 32, Abstract 246
62. Young J. Sildenafil (Viagra®) in the treatment of erectile dysfunction: A 12-week, flexible-dose study of assess efficacy and safety. The 8th World Meeting on Impotence Research, 25-28 August 1998, Amsterdam. Int J Impot Res 1988; 10 (Suppl. 3): S 34, Abstract 253
63. Montorsi F, McDermott TE, Morgan R et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011-1018
64. Dinsmore WW, Hodges M, Hargreaves C et al. Sildenafil citrate (Viagra®) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800-805
65. Feldman R, Waterbury CT and the Sildenafil Study Group. Sildenafil in the treatment of erectile dysfunction: efficacy in patients taking concomitant antihypertensive therapy. Am J Hypertension 1998; 11: 10A
66. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group JAMA 1999; 280: 421-426
67. Giuliano F, Hultling C, El Masry WS, Smith MD, Osterloh IH, Orr M, Maytom M. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999; 46: 15-21
68. Zippe CD, Kedia AW. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra®). Urology 1998; 52: 963-966
69. Hackett G, Gingell C et al. Long-term safety and efficacy after 2 years of Viagra® (sildenafil citrate) treatment in erectile dysfunction and the overall incidence of myocardial infarction. J Urol 1999; 161: 214A
70. Wagner G, Maytam M, Smith MD et al. Analysis of the efficacy of sildenafil (Viagra®) in the treatment of male erectile dysfunction in elderly patients. J Urol 1998; 157: 912A
71. Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999; 53: 775-778
72. Drory Y, Shapira Y, Fishman EZ et al. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 835-837
73. Drory Y, Fisman EZ, Shapira Y et al. Ventricular arrhythmias during sexual acitivty in patients with coronary artery disease. Chest 1996; 109: 922-924
74. Jackson G, Benjamin N, Jackson N et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C
75. Conti CR, Pepine CJ, Sweeney M et al. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83: 29C-34C
76. Webb DJ, Freestone S, Allen MJ et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C-28C
77. Muirhead CJ, Allen MJ, James GC et al. Pharmacokinetics of sildenafil (VIAGRA), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Brit J Clin Pharmacol 1996; 42: 259-282
78. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998 Nov-Dec; 20(6): 1033-1048
79. Arzneimittel-Kommission der deutschen Ärzteschaft. Hinweis zur sicheren Anwendung von Sildenafil (Viagra®). Deutsches Ärzteblatt 1998; 95: B-2013-1-B2014
80. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57: 967-989